Up 3% to €5.1m, first-half sales exceeded the €5m mark for the first time, despite four months of temporary absence of one of the top-performing surgeons in the United States
U.S. sales rose by 10% to $4.5m, or 3% to €3.9m
Continued expansion of the network in the United States, with 5 new centers added to the network and 13 new surgeons who have performed their first implants
As of the end of June 2026, SMAIO's solutions (patient-specific rods K-ROD or complete Kheiron fixation system) have been registered at more than 20 centers in the United States, representing more than 34 surgeons who should contribute to sustained and diversified long-term sales growth in North America
Strong cash position of €7.0m as of June 30, 2026, enabling the company to confidently pursue its development strategy
Webconference in French today at 6 pm CEST:
DALLAS & LYON, France, July 16, 2026--(BUSINESS WIRE)--Regulatory News:
SMAIO (Software, Machines and Adaptive Implants in Orthopaedics – Euronext Growth Paris, ISIN Code: FR0014005I80 / Ticker: ALSMA, eligible for the PEA-PME scheme), a French-American player specialized in complex spine surgery, offering an integrated pre, intra, and post-operative solution based on a 3D planning software, adaptive implants, and related services, today announced its sales and cash position as of June 30, 2026.
Philippe ROUSSOULY, Chairman and CEO of SMAIO, stated: "SMAIO is continuing its commercial expansion in the United States, driven by solid underlying momentum, as evidenced mainly by the growing number of surgeons choosing our solutions. Our hospital network expanded further during the half-year, with 5 new centers of excellence added to our network and 13 surgeons performing their first procedures using our solutions, which provides a diversified foundation for our long-term growth.
Our North American sales rose by 10% to $4.5 million for the half-year, or 3% to €3.9 million after adjusting for the unfavorable euro/dollar exchange rate, which had a negative impact of €0.3 million over the period. Despite this, the Group's half-year sales exceeded the €5 million threshold for the first time, reaching €5.1 million, representing a 3% increase. In addition, the move in early March of one of the main North American users of our Kheiron system to one of the most renowned university hospitals on the West Coast - where Kheiron was not yet registered - resulted in a transition period during which no surgeries were performed. This temporary interruption resulted in a significant shortfall in sales compared to the revenue generated with this customer during the same period in 2025, even though its Kheiron activity had been growing very strongly at the start of the year at its previous hospital. Since registration at the new center was finalized in mid-June and the first Kheiron system implantation there is scheduled for July, the negative impact of this move on SMAIO's monthly sales should gradually fade.